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Regulatory T (Treg) cells limit the onset of effective
antitumor immunity, through yet-ill-defined mecha-
nisms. We showed the rejection of established oval-
bumin (OVA)-expressing MCA101 tumors required
both the adoptive transfer of OVA-specific CD8+
Tcell receptor transgenicTcells (OTI) and theneutral-
ization of Foxp3+ T cells. In tumor-draining lymph
nodes, Foxp3+ T cell neutralization induced amarked
arrest in the migration of OTI T cells, increased
numbers of dendritic cells (DCs), and enhanced OTI
T cell priming. Using an in vitro cytotoxic assay and
two-photon live microscopy after adoptive transfer
of DCs, we demonstrated that Foxp3+ T cells induced
the death of DCs in tumor-draining lymph nodes, but
not in the absence of tumor. DCdeath correlatedwith
Foxp3+ T cell-DC contacts, and it was tumor-antigen
and perforin dependent. We conclude that Foxp3+
T cell-dependent DC death in tumor-draining lymph
nodes limits the onset of CD8+ T cell responses.INTRODUCTION
Regulatory T (Treg) cells represent a population of Foxp3-
expressing, CD4+, CD25+ T cells that play a key role in the
control of autoimmune disorders but also restrict antitumor
immune responses (North and Bursuker, 1984). Treg cells repre-
sent 5 to 10% of the CD4+ T cells in secondary lymphoid organs
and can expand and accumulate in many types of tumors, sug-
gesting that they participate in the inhibition of antitumor immune
responses (Wang and Wang, 2007). However, the reasons for
Treg cell expansion and accumulation during tumor develop-
ment, and in particular the antigen specificity of the expanded
cells, remain unclear (Hsieh et al., 2004; Pacholczyk et al.,
2007). Treg cell accumulation in tumor-bearing animals may
result from either proliferation of thymic differentiated Foxp3+
T cells (natural Treg cells) or the conversion of Foxp3CD4+266 Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc.T cells into Foxp3+CD4+ T cells (induced Treg cells), depending
on the tumor models (Colombo and Piconese, 2007). Because
tumor cells might express tumor-associated antigens or tumor-
specific antigens, as well as a vast variety of self-antigens,
tumor-specific and self-specific Foxp3+ T cells might be present
in the tumor microenvironment. These Treg cells may suppress
antitumor responses after activation by either tumor-related or
tumor-unrelated other self-antigens.
The mechanisms of suppression of antitumor CD8+ T cell
responses by Treg cells are still unclear. In certain models,
Treg cells suppress priming (Somasundaram et al., 2002; Woo
et al., 2002), acting on antigen-presenting cells (Cederbom
et al., 2000; Lewkowich et al., 2005; Misra et al., 2004). In other
models, Treg cells suppress the effector phase (Appay et al.,
2006; Yu et al., 2005) through direct action on T cells, involving
IL10 or TGF-b (Ostroukhova et al., 2006; Chen et al., 2005; Green
et al., 2003), as well as through IL-2-deprivation (Pandiyan et al.,
2007) or cyclic-AMP transfer through gap junctions (Bopp et al.,
2007).
A cytotoxic-dependent mechanism for Treg cell suppression
has been proposed in several studies. Foxp3+ T cells are cyto-
toxic to different cell types, including CD8+ T, NK, and B cells,
depending on the models, through granzyme B-, perforin-, or
Fas-FasL-dependent cytotoxic pathways (Cao et al., 2007;
Grossman et al., 2004; Janssens et al., 2003; Zhao et al.,
2006). Cao et al. (2007) also show that Treg cells induced in
tumor-bearing animals express both perforin and granzyme B.
At least in one of these models, target recognition was antigen
specific (Janssens et al., 2003), thus selectively targeting MHC
class II-expressing antigen-presenting cells.
No doubt that dynamic intravital imaging of Treg cell functions
could clarify their mechanisms of action in vivo. Two indepen-
dent studies in models of diabetes and experimental autoim-
mune encephalitis have recently imaged Foxp3+ T cells with
two-photon intravital microscopy. Both studies concluded that
Foxp3+ T cells affect autoreactive naive conventional CD4+
T cell dynamics in lymph nodes (Tadokoro et al., 2006; Tang
et al., 2006), thereby preventing their arrest on antigen-present-
ing cells during priming. These imaging results indicate that
Foxp3+ T cell-mediated inhibition of autoimmune responses
occurs, at least in part, early during the priming phase in lymph
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Figure 1. Foxp3+CD25+TCellNeutralization
Induces Tumor Rejection after Antigen-
Specific CD8+ T Cell Adoptive Transfer
(A) MCA-OVA tumor cells were inoculated in the
flank of mice treated (black) or not treated (white)
with anti-CD25 (PC61). Naive OTI T cells were
adoptively transferred (right panel) or not trans-
ferred (left panel) at day 10, and tumor growth
was monitored. Graphs represent mean ± SEM
values obtained with 22 mice in each group, from
five independent experiments (right panel) and
eight mice in each group from two independent
experiments (left panel).
(B) Representative dot plots of CD25 and GFP
expression on CD4+ T cells at d10 in tdLN of
Foxp3-EGFP tumor-bearing mice treated or not
treated with anti-CD25 as indicated.
(C) The percentage of total cells (upper panels) and
absolute numbers (lower panels) of Foxp3CD4+,
Foxp3+CD4+, and CD25+Foxp3+CD4+ cells were
monitored 1, 6, and 10 days after treatment with
PC61 (black) or rat IgG1 isotype (white). Results
are the mean ± SEM of 10 to 13 mice from three
to four independent experiments.
Immunity
Dendritic Cell Killing by Foxp3+ T Cellsnodes. Nevertheless, Foxp3+ T cells also reduce granule exocy-
tosis in effector cytotoxic T lymphocytes (CTLs) in vivo (Mempel
et al., 2006). This inhibitory effect did not require long-lasting
contacts between Foxp3+ T cells and CTLs, but was dependent
on their responsiveness to TGF-b. Altogether, these results show
that both the initiation of immune responses in lymph nodes, and
the effector phases, may potentially be affected by Foxp3+
T cells. All the imaging experiments in these studies were per-
formed with adoptively transferred, TCR-transgenic, high-affinity
Treg cells. Because the affinity of the TCRs influences the
dynamics of T cell-DC interactions (Skokos et al., 2007), the
analysis of polyclonal Foxp3+ T cells should be very informative.
Here, we have analyzed the interactions between endogenous
polyclonal Foxp3+ T cells and DCs in tumor-draining lymph no-
des. We have shown that Foxp3+ T cells limit DC survival in the
tumor-draining lymph node (tdLN) through an antigen- and per-
forin-dependent mechanism, involving direct contacts between
Foxp3+ T cells and tumor-antigen presenting DCs.
RESULTS
Foxp3+CD25+ T Cells Inhibit Antitumor CD8+ T Cell
Responses and Tumor Rejection
To analyze the mechanisms of the Foxp3+ T cell-mediated
suppression of antitumor CD8+ T cell responses, we used a
methyl-cholanthrene-induced fibrosarcoma cell line, MCA101
(called MCA thereafter), expressing a model antigen, ovalbumin
(OVA). MCA-OVA cells grow as solid subcutaneous (s.c.) synge-
neic tumors after inoculation in C57Bl/6 (B6) mice (Figure 1A).
Injection of anti-OVA transgenic CD8+ T cells (OTI T cells)
10 days after tumor inoculation induced a transient reduction
in the rate of tumor growth, but no tumor rejection (Figure 1A).
The potential role of Foxp3+ T cells was first addressed with
PC61, a CD25 monoclonal antibody previously shown to abolish
Treg cell-mediated suppression of antitumor immune responses
(Onizuka et al., 1999). The adoptive transfer of OTI T cells to micepreviously treated with anti-CD25 induced effective rejection of
MCA-OVA (Figure 1A), but not of MCA tumors (not shown).
In order to avoid as much as possible any interference of the
anti-CD25 with OTI T cell priming, we injected the anti-CD25
10 days before the adoptive transfer of OTI T cells. At the time
of OTI T cell adoptive transfer, the anti-CD25 serum concentra-
tion was very low (100 ng/ml). This serum concentration was
1/10 of the concentration of an isotype control (HRNP, injected
under the same conditions), suggesting that the anti-CD25
disappears from the blood (as soon as 2 hr after injection)
because of binding to CD25+ cells (Figure S1A available online).
In the absence of OTI T cell transfer, anti-CD25 treatment failed
to induce tumor rejection (Figure 1A), indicating that the endog-
enous antitumor immune response was insufficient to reject the
tumor in this system.
To investigate the effect of the anti-CD25 treatment on
Foxp3+CD25+ T cells, we analyzed their frequency and absolute
numbers in the tdLNs, as compared to Foxp3 T cells (Figures
1B and 1C and Figure S1B). The numbers of both CD4+Foxp3+
and CD4+Foxp3 T cells increased after tumor inoculation.
The increased number of Foxp3+ T cells in tumor-bearing mice
was due to the expansion of natural Foxp3+ T cells, rather than
the conversion of CD4+Foxp3cells to CD4+Foxp3+ cells. Indeed,
upon adoptive transfer of CD4+Foxp3 T cells sorted from Foxp3-
EGFP mice into tumor-bearing B6 mice, the cells expanded but
did not convert to CD4+Foxp3+ T cells (not shown). The most
striking effect of the anti-CD25 was a strong reduction of both
the absolute numbers and the proportion of CD4+CD25+ T cells.
The down modulation of surface CD25 was confirmed with the
7D4 clone, an anti-CD25 recognizing a different epitope from
the one used for the injection (not shown). The anti-CD25 did
not affect the expansion of CD4+Foxp3, but reduced by 20%–
40% (depending on the experiments) the percentage of Foxp3+
T cells in tdLNs 6–10 days after tumor inoculation (Figure 1C).
The anti-CD25 treatment did not deplete Foxp3+ T cells, but
affected their accumulation (reduction of 25%, Figure 1C). KI67Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc. 267
Immunity
Dendritic Cell Killing by Foxp3+ T Cellsstaining of Foxp3+ T cells showed that their proliferation was not
reduced (not shown). This discrepancy could be explained either
by a defect in survival of Foxp3+CD25+ T cells after treatment and/
or preferential proliferation of CD4+Foxp3+CD25 T cells that
were not affected by anti-CD25 treatment (Couper et al., 2007;
Kohm et al., 2006; Zelenay and Demengeot, 2006). Therefore,
even though anti-CD25-treated mice still bear Foxp3+CD25
T cells, these cells do not suppress tumor rejection by OTI
T cells because of their reduced numbers, their decreased activity
(due to the lack of CD25 expression), or both.
Tumor inoculation induced a wide activation of Foxp3+ T cells,
as reflected by the increased proportion of CD69+ and CD44hi
Foxp3+ T cells after tumor inoculation in both tdLNs and non-
draining LNs (more than 90% of the Foxp3+ T cells were
CD44hi in tumor-bearing mice) showing a systemic activation
of Foxp3+ T cells (Figure S1C). Whether these Foxp3+ T cells
were specific for self-antigens or tumor-specific antigens is
unknown. The percentage of CD62Lhi Foxp3+ T cells in the tdLNs
increased during tumor growth, suggesting that the CD62Llo
Foxp3+ T cells migrated elsewhere. Indeed, we observed that
within the tumor, the Foxp3+ T cells exhibited a strongly acti-
vated phenotype with high expression of CD44, low expression
of CD62L, and a high percentage of CD69hi cells, arguing for
a recruitment of antigen-specific Foxp3+ T cells to the tumors.
Injection of the anti-CD25 did not modify the proportion of
CD69hi, CD44hi+, or CD62Lhi Foxp3+ T cells, neither in LNs nor
in the tumors (Figure S1C). Therefore, MCA-OVA tumors induce
Foxp3+ T cell expansion and activation.
Analysis of Foxp3+ T Cells Motility in Tumor-Draining
Lymph Nodes
In order to image endogenous Foxp3+ T cells in lymph nodes, we
used B6 knock-in mice expressing an IRES-EGFP cassette in the
30 untranslated region of the Foxp3 gene (Foxp3-EGFP mice)
(Wang et al., 2008). Endogenous Foxp3+ T cells in LNs are
organized as a very dense swarm of motile cells that migrate
with a mean velocity of 5.8±3.6mm/min (Figures S1D–S1F;
Movies S1 and S2). Foxp3+ T cell motility, in terms of mean
velocity, confinement ratio, and arrest coefficient, was similar
in the LNs of mice bearing tumors or not. In addition, the anti-
CD25 treatment did not affect the motility of the remaining
Foxp3+ T cells (Figures S1E and S1F). The detailed analysis of
the distribution of the motility of the Foxp3+ T cells, revealed
the presence of both highly motile (crawling) and nearly arrested
cells (swarming) (Figures S1D–S1F). This heterogeneity maybe
due to the fact that we imaged polyclonal endogenous Foxp3+
T cells displaying a highly diverse, most likely anti-self antigen-
specific, TCR repertoire (Hsieh et al., 2004) (the potential
recognition of self epitopes may reduce the global motility of
the cells).
The mean velocity observed for polyclonal Foxp3+ T cells is
lower than that previously determined for conventional CD4+
T cells (Vmean: 10 mm/min [Miller et al., 2004]). We therefore
compared the motility of endogenous Foxp3+ T cells to that of
adoptively transferred CMTMR-labeled naive Marilyn CD4+
T cells, in both tumor-bearing and tumor-free mice (Figure S1E).
Interestingly, the motility of Marilyn CD4+ T cells was lower in
tdLNs (Vmean: 5.9 ± 2.9 mm/min) than in the same LNs in the
absence of tumor (Vmean: 7.8 ± 2.3 mm/min). In contrast, as268 Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc.described above, the mean velocity for Foxp3+ T cells was simi-
larly low in the absence or presence of tumors. This observation
suggests that the motility of polyclonal Foxp3+ T cells is lower
than conventional CD4+ Foxp3 T cell motility, in tumor-free
animals, but similar in tdLNs. Nevertheless, we cannot exclude
that such dissimilarity in the mobility of CD4+Foxp3 and CD4+
Foxp3+ T cells is due to differences between endogenous and
adoptively transferred T cells.
Foxp3+CD25+ T Cells Inhibit the Arrest of Antitumor
CD8+ T Cells in Tumor-Draining Lymph Nodes
We have shown previously that during the onset of effective
cytotoxic antitumor responses, CD8+ T cells establish stable,
long-lasting contacts with antigen-presenting DCs (Hugues
et al., 2006; Scholer et al., 2008). These stable interactions
induce a strong arrest of CD8+ T cells in tdLNs. We therefore
decided to analyze in more detail the effect of Foxp3+CD25+
T cell inactivation or depletion on OTI T cell dynamics early
(20 hr) after their adoptive transfer to tumor-bearing mice
(Figures 2A–2C). We have shown previously that at this time
point, OTI T cells arrested their migration in LNs draining immu-
nogenic EL4 tumors expressing OVA (EG7 tumors) (Scholer
et al., 2008). In order to analyze the dynamics of OTI T cell migra-
tion, we adoptively transferred CFP-expressing OTI T cells to
Foxp3+-EGFP mice. As shown in Figure 2, OTI T cell motility
(mean velocity, confinement ratio, and arrest coefficient) was
similar in LNs draining MCA-OVA tumors (Movie S1), in LNs
draining MCA tumors that did not express OVA, or in LNs in the
absence of tumors. Therefore, OVA-expressing MCA tumors, in
contrast to EG7 tumors (which were rejected even in the pres-
ence of Foxp3+ T cells [Scholer et al., 2008]), did not affect OTI
T cell motility in tdLNs, consistent with the absence of effective
antitumor immune responses and tumor rejection in these mice.
In contrast, Foxp3+CD25+ T cell inactivation by the anti-CD25
antibody induced a marked arrest in OTI T cell motility, in the
MCA-OVA-draining LNs (Figures 2A–2C; Movie S2). The mean
velocity dropped from 6.8 ± 3.3 mm/min to 3.6 ± 2.6 mm/min
(p < 0.0001), and the confinement ratio decreased from 0.6 ±
0.22 to 0.44 ± 0.21 (p < 0.0001). The arrest coefficient, in
contrast, increased from 19% ± 24% to 45% ± 29% (p <
0.0001). This change in OTI T cell motility was not observed in
the popliteal LNs (ndLNs) of the same animals (Figure S2A) or
in the axillary LNs of animals bearing MCA tumors that did not
express OVA (Figure 2B).
We previously have shown that stable T-DC interactions
correlate with efficient CD8+ T cell priming (Hugues et al.,
2004; Scholer et al., 2008). Therefore, we investigated the effect
of Foxp3+CD25+ T cell inhibition on OTI T cell priming. To do
so, we adoptively transferred OTI T cells 10 days after tumor
inoculation to mice treated or not treated with anti-CD25 and
analyzed OTI T cell activation, proliferation, and differentiation.
Foxp3+CD25+ T cell inactivation did not affect CD69 expression
or the rate of division of the transferred OTI T cells (Figures S2B
and S2C). Treatment with anti-CD25 antibody, in contrast,
favored OTI T cell accumulation and increased the production
of IFN-g in tdLNs (Figures S2D and S2E). We concluded that
the decreased motility of OTI cells observed upon Treg cell inac-
tivation correlates with more efficient priming (increased T cell
numbers and IFN-g production).
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Figure 2. Foxp3+ CD25+ T Cells Inhibit CD8+ T Cells Arrest during
Priming in Tumor-Draining Lymph Nodes
Twenty hours after adoptive transfer of CFP-expressing OTI T cells in tumor-
bearing or tumor-free Foxp3-EGFP mice, OTI T cell motility was analyzed by
two-photon imaging in explanted LNs as indicated.
(A) Time-lapse two-photon microscopy images. OTI T cells are shown in blue,
Foxp3+ T cells shown in green; and the white bar represents 35 mm. Typical OTI
T cell track paths are represented (white lines).
(B) OTI T cells were individually tracked and the mean velocity (upper panel),
the confinement ratio (middle panel), and the arrest coefficient (lower panel)
were determined. The box extends from the 25th to the 75th percentile, the
line at the middle is the median and the error bars extend from the lowest up
to the highest values. Graphs represent pooled data from at least three inde-
Immunity
Dendritic Cell Killing by Foxp3+ T CellsFor confirmation of these observations in another experi-
mental model, Foxp3+ T cells were genetically depleted with
diphteria toxin (DTx) in mice expressing the DTx receptor under
the control of the Foxp3 promoter (DEREG mice, Lahl et al.,
2007). As described previously, Foxp3+ T cells were fully
depleted after two consecutive injections of DTx (Figure S3A).
As the reappearance of emigrating Foxp3+ T cells occurred
within 4 to 5 days, depletion was maintained by DTx treatment
every 4 days. During the period of tumor growth, no mortality
was observed.
Foxp3+ T cell depletion in DEREG mice also induced effective
tumor rejection (Figure S3B) and OTI T cell motility in the tdLNs
was reduced, but not as strongly as after PC61 treatment
(Figure S4C). This difference could reflect the fact that in these
mice, OTI T cells were more clustered and distributed closer to
the subcapsular area, as compared to control LNs (not shown).
It is noteworthy that we observed some slight differences in
OTI T cell motility between DEREG mice and littermate controls
in the absence of DTx treatment, suggesting a basal transgene
effect. In addition, the proliferation rate and the production of
IFN-g by OTI T cells were both increased after treatment with
DTx, as compared to treated littermates (Figures S3D and S3E).
We conclude that Foxp3+CD25+ T cell inactivation (with anti-
CD25 antibodies) or depletion (with DTx) enhanced OTI T cell
priming in mice bearing MCA-OVA tumors.
Foxp3+CD25+ T Cells Control the Number of DCs
in Tumor-Draining Lymph Nodes
By presenting antigen to T cells, DCs determine their motility in
lymph nodes. T cell arrests depend on several parameters,
including the density of antigen-presenting DCs, their maturation
state, and the amounts of antigen presented on the DCs (Celli
et al., 2007; Hugues et al., 2004; Scholer et al., 2008). The effect
of Foxp3+CD25+ T cell inactivation on CD8+ T cell motility could
therefore be due to a modulation of DC functions by
Foxp3+CD25+ T cells. Given that several studies reported that
Foxp3+ T cells can modify DC maturation in vitro (Cederbom
et al., 2000; Lewkowich et al., 2005; Misra et al., 2004), we first
analyzed the maturation profile of the DCs in tdLNs, 10 days
after tumor inoculation in anti-CD25 treated or untreated mice
(in the absence of OTI T cell transfer). As shown in Figure 3A,
the surface expression of CD80, ICAM-1, I-Ab, and CD40 on
DCs was not modified by the anti-CD25 treatment. Similar results
were observed in DEREG mice (not shown). These results,
however, do not exclude the possibility that Foxp3+ T cells affect
maturation in a subpopulation of DCs, which we may have missed
in this global FACS analysis.
In contrast, we observed a clear increase in both the
percentage and the absolute numbers of CD11chi cells in tdLNspendent experiments. n = 180 OTI T cells for draining lymph nodes (dLNs) of
tumor-free mice; n = 169 for draining lymph nodes of MCA-bearing mice;
n = 863 for draining lymph nodes of MCA-bearing mice with anti-CD25;
n = 777 for draining lymph nodes of MCA-OVA-bearing mice, and n = 416
for draining lymph nodes of MCA-OVA-bearing mice with anti-CD25.
(C) Distribution of OTI T cells as a function of their mean velocity (higher panel),
confinement ratio (middle panel), and coefficient arrest (lower panel) in the
draining lymph node of MCA-OVA-bearing mice treated (orange) or not treated
(red) with anti-CD25 or in the draining lymph node of MCA-bearing mice
treated (light blue) or not treated with anti-CD25 (dark blue).
Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc. 269
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Figure 3. Foxp3+ CD25+ T Cells Limit DC
Numbers in Tumor-Draining Lymph Nodes
Ten days after tumor inoculation, DC maturation
profile and numbers were determined in tdLNs of
mice treated or not treated with anti-CD25.
(A) Surface expression of CD80, ICAM-1, I-Ab, and
CD40 were analyzed by flow cytometry after
gating on CD11chi population. Histograms repre-
sent expression profiles of these maturation
markers (full histograms are isotype controls).
Graphs represent the mean fluorescence intensity
of these maturation markers (data are pooled from
three independent experiments). Each bar repre-
sents a mean ± SD.
(B) Quantification of DC percentage in lymph
nodes by flow cytometry. Representative dot plots
of CD11chi population in tumor-draining lymph
nodes of mice treated or not treated with anti-
CD25 (left panel). CD11chi percentage (middle
panel) and number (right panel) in lymph nodes
of tumor-free mice and in draining lymph nodes
(dLNs) and nondraining lymph nodes (ndLNs) of
tumor-bearing mice are shown. For comparison
of the percentages and numbers of CD11chi cells
in several experiments, the results were normal-
ized and plotted as a percentage (as described
in the material and methods). Bars represent
mean ± SD of different mice from three to eight
independent experiments.
(C) Quantification of DC percentage in lymph
nodes by flow cytometry. Representative dot plots
of CD11chi population in tumor-draining lymph
nodes of littermate and DEREG (left panel).
Increase percentage and number of CD11chi cells
in DEREG mice and littermate after DTx treatment
were normalized as in (B). For all conditions raw
mean ± SD of DC percentages and numbers are
indicated in Figure S4.
Immunity
Dendritic Cell Killing by Foxp3+ T Cellsof anti-CD25-treated mice, as compared to untreated mice (of
50% and 100%, respectively) (Figure 3B and Figures S4A–
S4D). These cells were also CD11b+ and I-Ab hi, suggesting
a myeloid origin (not shown). Accumulation of CD8 and CD8+
DCs was similarly modified by the anti-CD25 treatment. This
increase in the percentage and the absolute numbers of CD11chi
cells upon injection of anti-CD25 was neither observed in non-
draining LNs nor in tumor-free mice. Similar accumulation of
DCs was observed in tumor-bearing DEREG mice after Foxp3+
T cell depletion (Figure 3C and Figures S4B–S4D). We conclude
that Foxp3+CD25+ T cells reduce the density of the endogenous
DC-network in tumor-draining lymph nodes. These results
suggest that tumor-activated Foxp3+ T cells modulate the
recruitment, the retention, and/or the viability of DCs in tdLNs.
Imaging of DC Death in Tumor-Draining Lymph Nodes
Foxp3+ T cells were previously shown to be cytotoxic in several
experimental models (Cao et al., 2007; Grossman et al., 2004;
Janssens et al., 2003; Zhao et al., 2006). We therefore analyzed
the possibility that Foxp3+ T cells control the viability of DCs in270 Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc.tdLNs. We were unable to detect any difference in the viability
of DCs in tdLN of mice treated or not treated with anti-CD25
using annexin V staining ex vivo (not shown). Because dying cells
are rapidly eliminated by phagocytosis in vivo and can be lost
during LN dissociation, we decided to further investigate this
point by using real-time imaging. We used an assay for in vivo
cytotoxicity previously described (Mempel et al., 2006). In vi-
tro-generated DCs were labeled with Hoechst (nuclear labeling)
and 5mM 5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetrame-
thylrhodamine (CMTMR, cytosolic labeling). DCs that lose their
cytosolic red CMTMR labeling when the plasma membrane
becomes permeable, while maintaining their nuclear blue
Hoechst labeling, and stopped moving were scored as ‘‘dying
DCs’’ (see Figure 4A and Movie S3).
In order to evaluate their survival after adoptive transfer to
MCA-OVA bearing mice, we transferred DCs loaded with the
I-Ab restricted OVA323-339 peptide to Foxp3
+-EGFP mice bearing
MCA-OVA tumors. The survival of the transferred DCs was
analyzed 18–24 hr later with two-photon dynamic microscopy
in the T cell zones (100–200 mm deep) in explanted LNs. The
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Figure 4. In Vivo Imaging of Foxp3+ T Cell-Mediated DC Death
Bone marrow-derived DCs were labeled with Hoechst (blue) and CMTMR (red) and injected s.c. 9 days after tumor inoculation in Foxp3-EGFP mice bearing or not
bearing a tumor. Mice were treated or not treated, as indicated, with anti-CD25 2 days after tumor inoculation. Tumor-draining lymph nodes were imaged with
two-photon microscopy 24 hours after DC adoptive transfer.
(A) Time-lapse two-photon microscopy images. Example of DC-death visualization 363 36 mm (white bar represent 10 mm). Histograms represent line-scan anal-
ysis of the fluorescence intensity emitted by Hoechst (blue line) or CMTMR staining (red line) of the indicated DC along time (lower panel).
(B) Rate of DC death along time. Transferred DCs were loaded with OVA323-339 peptide (1 mM) and injected in WT tumor-bearing mice. The graph represents the
mean ± SEM percentage of dying DCs along time from 11 movies from 6 independent experiments.
(C–E) Percentage of dying DCs observed in different experimental conditions as indicated. Each dot represents the percentage of dying DCs in a single movie
(10–100 DCs were analyzed per movie). As shown in (C), transferred DCs were loaded with OVA323-339 peptide (1 mM) and injected in tumor-bearing mice treated
as indicated. As shown in (D), WT or I-Ab/ DCs loaded or not loaded with OVA323-339 peptide were injected as indicated in tumor-bearing mice. As shown in (E),
transferred DCs were loaded with OVA323-339 peptide and injected into mice bearing a tumor or not. Gray bars represent the median of the percentages of dying
DCs out of two to ten independent experiments.
(F) Longest contact duration between Foxp3+ T cells and DCs are represented for DCs that are going to die or remain alive during the imaging period: living
(L) versus dead (D). Each dot represents one DC. Bars represent the medians.
(G) Frequency of DC death as a function of the longest Foxp3+ T cell-DC contact duration. Bars represent the proportion of living (white) and dying (black) DCs.
DCs were loaded or not loaded with OVA323-339 peptide (1 mM) and injected in mice treated or not treated with anti-CD25, as indicated. Numbers above the bars
indicate the numbers of cells analyzed.
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Dendritic Cell Killing by Foxp3+ T Cellsproportion of dying DCs in the 1-hr-long movies was quite vari-
able, ranging from 0% to more than 55% of the DCs in each
imaging field, with a constant rate over time (Figure 4B). In
more than 30 movies, from over ten independent experiments,an average of 27% ±16% of the DCs in each field were found
to die during the imaging period (Figure 4C). In order to address
the possibility that Foxp3+CD25+ T cells control DC viability in
tdLNs, we treated the animals with anti-CD25 before DCImmunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc. 271
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Dendritic Cell Killing by Foxp3+ T Cellsadoptive transfer. Alternatively, we depleted Foxp3+ T cells by
using DTx in DEREG mice. The inactivation of Foxp3+CD25+
T cells by anti-CD25 or Foxp3+ T cell depletion by DTx both
strongly decreased the proportions of dying DCs (Figure 4C,
Movies S4 and S5), indicating that DC death in tdLNs is
Foxp3+ CD25+ T cell dependent. We observed large autofluores-
cent cells in tdLNs from anti-CD25- and DTx-treated mice (Movie
S5 and data not shown), and such cells may represent macro-
phages that have phagocytosed dying Foxp3+ T cells.
Both CD8+ T cells (Guarda et al., 2007) and NK cells (Yu et al.,
2006) were shown previously to kill DCs under different condi-
tions. To investigate the potential involvement of these two cell
types in the DC death observed in tumor-bearing mice, we
depleted these two cell populations by treating tumor-bearing
mice with anti-CD8 and anti-NK1.1 before the adoptive transfer
of the DCs. As shown in Figure 4C, CD8+ T cell and NK cell deple-
tion did not affect DC death in tdLNs. We conclude that Foxp3+
T cells can modulate the survival of DCs in tdLNs.
The requirements for the control of DC viability by Foxp3+
T cells in tdLNs were further characterized. Only few DCs died
when they were not loaded with the OVA323-339 peptide or
were deficient for MHC class II molecules (respectively 7.6%
and 6.6% dying DCs) (Figure 4D). Likewise, no significant DC
death was observed when OVA323-339 peptide loaded DCs
were adoptively transferred to tumor-free mice (Figure 4E).
Phototoxic effects due to DC labeling (Hoechst and CMTMR)
and laser-light exposure might induce DC death and thus
interfere with our quantification. Arguing against this possibility,
we first showed that the rate of DC death is constant over time
(Figure 4B) and, secondly, it is very unlikely that this phototoxic
effect happens only in a single experimental condition (for class
II MHC-sufficient DCs, loaded with the OVA323-339 peptide and
transferred into tumor-bearing mice in the presence of fully func-
tional Foxp3+ T cells). Moreover, we quantified DC death without
any prior continuous light exposure, by taking single-shot images
of randomly chosen fields from tdLNs. Again, DC death was
higher when DCs were loaded with the OVA323-339 peptide, as
compared to unloaded DCs (39% ±23% versus 18% ± 11%,
respectively, p < 0.0001) (Figure S5A) showing antigen-depen-
dent DC death in the absence of prolonged exposure to laser light.
We conclude that the control of DC viability by Foxp3+ T cells
is MHC class II restricted and antigen dependent and requires
the presence of a tumor.
Analysis of DC-Foxp3+ T Cell Interactions
in Tumor-Draining Lymph Nodes
In order to further investigate the role of Foxp3+ T cells in DC
death in tdLNs, we analyzed the dynamic interactions between
these two cell types. To do so, we imaged polyclonal Foxp3+
T cells in Foxp3-EGFP mice after adoptive transfer of labeled
DCs. In many cases, we observed death of DCs while they
were interacting tightly with one or more Foxp3+ T cells (Movie
S6). In order to quantify these interactions, we defined three
parameters that quantify the interactions of each DC with
Foxp3+ T cells: (1) the frequency of contacts (interaction number/
hour, represents the number of contacts that each DC estab-
lishes with Foxp3+ T cells, normalized to the density of Foxp3+
T cells in each movie), (2) the cumulative contact duration (addi-
tion of the durations of all the individual contacts established by272 Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc.a DC with Foxp3+ T cells during 1 hr, normalized to the density
of Foxp3+ T cells in each movie), and (3) the duration of the
longest contact with a Foxp3+ T cell for each DC.
These parameters were similar in untreated and anti-CD25-
treated animals, and when DCs were sensitized or not sensitized
with OVA323-339 peptide. In contrast, in the absence of MHC
class II expression on the DCs, all three parameters were signif-
icantly reduced. The reduction in the frequency of contacts
between Foxp3+ T cells may reflect a reduction in the contact
duration, given that contacts shorter than 30 s (the interval of
our imaging) can be missed. These results indicate that contacts
between DCs and Foxp3+ T cells in tdLNs are dependent on
class II MHC expression on DCs.
In order to further investigate the possible relationship
between the observed DC-Foxp3+ T cell contacts and DC death,
we analyzed separately the DCs that were going to die and those
that remained alive during each movie. The different parameters
described above were quantified in each of the two groups.
Figure 4F and Figure S5B show that the frequency of the
Foxp3+ T cell-DC contacts was not different between the DCs
that were going to die and those that remained alive. In contrast,
the DCs that were going to die established longer contacts with
Foxp3+ T cells than those that remained alive, as outlined both by
the cumulative contact duration (mean of 13.4 ± 13.2 min for
living DCs versus 23.4 ± 22 min for dying DCs, p < 0.0001)
(Figure S5B) and the longest contact duration (mean of 5.1 ±
5.9 min for living DCs versus 13.4 ± 9.6 min for dying DCs, p <
0.0001) (Figure 4F). These long lasting contacts of Foxp3+
T cells with DCs that were going to die were not observed with
DCs that did not express MHC class II molecules.
The analysis of the proportion of dying DCs as a function of the
duration of the longest contact showed that DCs that established
longer contacts with Foxp3+ T cells had a higher probability to
die than DCs that established shorter contacts (more than
80% of the DCs that establish contacts longer than 15 min
with Foxp3+ T cell died during the movies, whereas only less
than 10% of the DCs that established contacts shorter than
5 min do so, Figure 4G). These results establish a direct relation-
ship between the duration of the DC-Foxp3+ T cell contacts and
the death of the DCs. The results also exclude the possibility that
DC death is due to phototoxicity during the movies, given that
there is no reason that phototoxic death affects selectively
DCs that interact more stably with Foxp3+ T cells. In addition,
we did not observe long-lasting contacts that started with DCs
already dead, indicating that Foxp3+ T cells do not adhere
‘‘nonspecifically’’ to dying cells. Individual representative exam-
ples of Foxp3+ T cells-DC interactions along time are shown in
Figure S5C. The vast majority of the Foxp3+ T cell-DC interac-
tions started before the CMTMR labeling started decreasing.
These observations show a correlation between long-lasting
contacts with Foxp3+ T cell and DC death, suggesting that the
long-lasting contacts are a cause, rather than a consequence,
of DC death. We conclude that Foxp3+ T cell-dependent DC
death involves direct contacts between these two cell types.
Foxp3+CD25+ T Cell-Mediated DC Death Is Perforin
Dependent
Foxp3+ T cells were previously shown to express perforin and
granzyme B and to kill target cells under different experimental
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Figure 5. DC Death Is Dependent on
Perforin Expression by Foxp3+ T Cells
(A) Representative histogram plot of perforin and
granzyme B expression in CD4+Foxp3 and
CD4+Foxp3+ T cells from either tumor-bearing or
tumor-free mice. Histogram bars represent the
quantification of perforin and granzyme B expres-
sion in tumor-bearing mice, as a fold increase
compared to the expression in tumor-free mice.
Values represent a mean ± SD of six mice from
two to three independent experiments.
(B) Quantification by two-photon imaging of DC
death in WT and Perf/ tumor-bearing mice.
Transferred WT DCs were loaded with OVA323-339
peptide.
(C and D) CD11chi percentage (C) and number (D)
in lymph nodes of Perf/ and littermate tumor-
bearing mice as determined by flow cytometry.
Data were normalized as described in Figure 3.
Bars represent medians of at least ten mice from
five independent experiments. For all conditions
raw mean ± SD of DC percentages and numbers
are indicated in Figure S4.
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Dendritic Cell Killing by Foxp3+ T Cellsconditions (Cao et al., 2007; Gondek et al., 2005; Grossman
et al., 2004; McHugh et al., 2002; Zhao et al., 2006). We therefore
tested the possibility that the Foxp3+CD25+ T cell-mediated DC
death observed above is perforin dependent. We first analyzed
the expression of perforin and granzyme B in Foxp3+ T cells
from tumor-free and tumor-bearing animals. As shown in
Figure 5A, in tumor-free mice, a significant proportion of
Foxp3+ T cells (13%) expressed perforin, whereas granzyme
B was found in almost 20% of the cells. The proportion of
CD4+Foxp3 T cells expressing these two markers was much
lower (4% and 8%, respectively). In tumor-bearing mice, the
respective proportions of perforin+ and granzyme B+ in CD4+
Foxp3+ T cells was significantly increased as compared to
tumor-free animals, but not significantly in CD4+Foxp3 T cells
(Figure 5A). Given that more than 90% of CD4+Foxp3+ cells
are also CD25+, we can conclude that perforin+ and granzyme
B+ Foxp3+ T cells are mainly CD25+.
To address the potential role of perforin in Foxp3+ T cell-medi-
ated DC death, we adoptively transferred WT DCs to perforin-
deficient tumor-bearing mice. As shown in Figure 5B, DC death
was strongly reduced in perforin-deficient mice, showing that
DC death required perforin expression. The lack of DC death
was not due to reduced Foxp3+ T cell numbers or activation,
which were both normal in perforin-deficient mice (not shown).
One prediction of these results is that the increase in DC
numbers that we observed after inactivation of Foxp3+ T cells
in tumor-bearing mice should also be perforin dependent. ToImmunity 32, 266–278,test this possibility, we analyzed the
percentages and absolute numbers of
DCs in the tdLNs of perforin-deficient
mice and in their perforin-sufficient litter-
mates. As shown in Figures 5C and 5D
and Figure S4C and S4D, both the
percentages and the absolute numbers
of CD11chi cells were increased in per-
forin-sufficient littermates, but not in per-forin-deficient mice after anti-CD25 treatment. We conclude
that the Foxp3+CD25+ T cell-dependent decrease in the
numbers of DCs in tdLNs is also perforin dependent.
The Adoptive Transfer of OTII Foxp3+ T Cell
to Perforin-Deficient Mice Reconstitutes DC Death
To investigate whether Foxp3+ T cells can kill DCs directly, we
performed an in vitro cytotoxicity assay using activated OVA-
specific (OTII) Foxp3+ and OTII Foxp3 T cells. The Foxp3+
OTII cells expressed greater amounts of perforin and granzyme
than the Foxp3 OTII cells (Figure 6A). The target DCs were iso-
lated from draining LNs of tumor-bearing or control mice and
labeled separately with two different concentrations of CFSE,
one of the two being also loaded with the OVA323-339 peptide.
After incubation with T cells, the proportion of CFSE high and
low target DCs was analyzed by flow cytometry. As shown in
Figure 6B, the Foxp3+ OTII cells killed LN DCs from both
tumor-bearing and control mice more efficiently that Foxp3
OTII cells.
In order to determine whether Foxp3+ T cell-mediated cyto-
toxicity also occurred in vivo, we adoptively transferred OTII
Foxp3+, OTII Foxp3, and HY-specific (Marilyn) Foxp3+ T cells
to perforin-deficient animals (in which we failed to see any DC
cytotoxicity, see Figure 5B). As shown in Figure 6C and in Movie
S7, the injection of OTII Foxp3+ T cells, but not of OTII Foxp3 or
Marilyn Foxp3+ T cells (specific for HY antigen and not OVA),
reconstituted the death of adoptively transferred peptide-loadedFebruary 26, 2010 ª2010 Elsevier Inc. 273
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Figure 6. Cytotoxic OTII-Foxp3+ Cells
Induce DC Death In Vivo
(A) Representative histogram plot of perforin and
granzyme B expression on OTII Foxp3+ (black)
and OTII Foxp3 (grey dashed) cells after 20 hr
of coculture with OVA323-339-loaded DCs.
(B) In vitro cytotoxicity assay by CFSE staining of
DCs loaded with OVA323-339 (CFSE
hi) or not
(CFSElo), isolated from tdLNs (left panel) and LNs
of tumor-free mice (right panel) in the presence
of in vitro-expanded OTII Foxp3+ cells (black)
and OTII Foxp3 cells (white). A representative
histogram plot for 20/1 T/DC ratio with percentage
of each population is shown. Graphs represent the
mean ± SEM of triplicates from two independent
experiments (lower panels).
(C) Quantification by two-photon imaging of DC
death in WT and Perf/ tumor-bearing mice
reconstituted or not reconstituted with OTII
Foxp3+ or Foxp3 or Marilyn Foxp3+ T cells as
indicated.
(D) Distribution of the percentage of dying DCs as
a function of the mean T cell/DC ratio in each
imaging field.
(E) Longest contact duration between living or
dying DCs and polyclonal (poly Foxp3+) or OTII
Foxp3+ T cells as indicated.
Immunity
Dendritic Cell Killing by Foxp3+ T CellsDCs in perforin-deficient mice. The frequency of the adoptively
transferred OTII Foxp3+ T cells in these animals was much lower
than that of endogenous Foxp3+ T cells. We were therefore able,
in this case, to analyze the proportion of dying DCs as a function
of the transferred T cells/DC ratio in each movie. As shown in
Figure 6D, DC death was proportional to the transferred T cell/
DC ratios (Spearman r = 0.58, *), indicating a role for the
Foxp3+ T cells present in each movie on DC death, as opposed
to a global effect of Foxp3+ T cells transfer on the tdLNs’ environ-
ment. The analysis of OTII Foxp3+ T cell-DC interactions
revealed that, in contrast to polyclonal Foxp3+ T cells, the dura-
tion of the longest contact for each DC was equally long (median
of 12 minutes) between DCs that are going to die or to stay alive
(Figure 6E). These contacts were as long as the ones between
polyclonal Foxp3+ T cells and the peptide-bearing DCs dying
during the movies, consistent with the possibility that the long-
lasting contacts of DCs with polyclonal Treg cells are actually
antigen specific. We conclude that the death of peptide-loaded
DCs in vivo mediated by adoptively transferred Treg cells is
antigen specific and perforin dependent.
DISCUSSION
We show here that the number of DCs in tdLNs increases after
Foxp3+ T cell inactivation or depletion in perforin-sufficient but
not in perforin-deficient animals. These results suggest that
DCs bearing tumor antigens maybe a target for Foxp3+ T cell-
mediated cytotoxicity in tdLNs. Using dynamic two-photon
imaging on explanted tdLNs, we found that adoptive transfer
of DCs expressing a model tumor antigen results in DC death
only when perforin-sufficient Foxp3+ T cells are present in the
mice. This antigen-specific cytotoxic activity was confirmed274 Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc.in vitro. Foxp3+CD25+ T cell inactivation or depletion in tumor-
bearing animals resulted in a marked arrest in antitumor CD8+
T cell migration, increased T cell priming, and subsequent tumor
rejection. These findings suggest a mechanism of inhibition of
the priming of anti-tumor CD8+ T cells by Foxp3+ T cells: by
inducing the death of the DCs that present high tumor-antigen
densities, Foxp3+ T cells decrease the amount of antigen present
in tdLNs, thereby preventing effective CD8+ T cell priming, in
particular IFN-g production. IFN-g plays a key role in the rejec-
tion of many different tumors in mice (Blankenstein, 2005). We
found that IFN-gR1-deficient mice failed to reject MCA101
tumors, even after the adoptive transfer of OTI cells and Treg
cell inactivation, suggesting an important role of IFN-g in our
tumor model (unpublished data). Therefore, the downregulation
of IFN-g production by regulatory T cell is most likely critical
for tumor rejection.
A central question raised by our results is whether Foxp3+
T cells kill DCs directly or determine their survival indirectly.
The first condition for the ‘‘direct killing’’ model is that DC death
should be the consequence of a direct contact with Foxp3+
T cells. In vitro, we show that activated Foxp3+ OTII T cells
are able to efficiently eliminate OVA323-339-loaded LN DCs
compared to Foxp3- OTII T cells. Our imaging results in vivo
show a strong correlation between the duration of the contact
and the death of the DCs: DCs that make contacts longer than
15 min with Foxp3+ T cells have a much higher probability to
die than DCs that make brief contacts (80% of the DCs that
made contacts longer than 15 min during the movies died). In
both the absence of class II MHC OVA peptide and in class II
MHC-deficient cells, the virtual absence of contacts longer
than 15 minutes correlated with low DC death. Our results also
show that the stable contacts are not a consequence of the
Immunity
Dendritic Cell Killing by Foxp3+ T Cellsdeath of DCs, because: (1) we never observed a Foxp3+ T cell
establishing a contact longer that 15 min after DC death, and
(2) the few dead DCs that were observed in the absence of
peptide, or in anti-CD25-treated mice, did not establish long
contacts with Foxp3+ T cells.
These results, however, do not exclude that the observed
stable interactions between living DCs and Foxp3+ T cells
correspond not to direct killing but, for example, to a putative
Foxp3+ T cell-mediated ‘‘help’’ of DC killing by other cytotoxic
cells. Arguing against this possibility, our results showed that
perforin expression in adoptively transferred OTII Foxp3+, but
not in OTII Foxp3, T cells is sufficient to cause DC death
similar to the in vitro cytotoxicity assay. In addition, depletion
of CD8+ T and NK cells, the two main perforin-expressing
cells, did not affect DC death in tdLNs. Altogether, these results
strongly suggest a ‘‘direct killing’’ model. Foxp3+ T cells have
already been shown in several independent studies to display
cytotoxic capacity (Cao et al., 2007; Grossman et al., 2004;
Janssens et al., 2003; Zhao et al., 2006). Whether or not a
particular tumor-dependent mode of activation of Foxp3+
T cells is required to become cytotoxic in vivo needs further
investigation.
One of the important characteristics of this study is that it
was almost entirely realized with endogenous polyclonal
Foxp3+ T cells. Foxp3+ T cell function was analyzed 10 days after
tumor inoculation. At this point, the mice’s immune system has
been exposed to both the tumor and the tumor antigens,
including OVA, during 10 days. We showed that this exposure
resulted in a marked activation of both CD4+Foxp3+ and
CD4+Foxp3 T cells. Given that the cytotoxic effects that we
have described are antigen dependent (only DCs presenting
the OVA class II-MHC peptide died after adoptive transfer), the
question of the antigen specificity of the Foxp3+ T cells present
in these tumor-bearing mice is relevant. It should be stressed
here that the observation that the death of adoptively transferred
DCs to tumor-bearing mice required the OVA peptide does
not mean that the Foxp3+ T cell response in the mice was
restricted to this tumor antigen. Indeed, in the tumor-bearing
mice, the T cells are exposed to a variety of tumor antigens, in
addition to OVA, that are phagocytosed by DCs in an inflamma-
tory environment. The adoptively transferred, in vitro-generated
DCs have not been exposed to any other tumor antigen. The
OVA class II MHC peptide used here was therefore the only
‘‘tumor’’ antigen present on these DCs. These results do not
exclude that other ‘‘tumor’’ or self-antigens are recognized by
Foxp3+ T cells on DCs in vivo. It proved to be very difficult,
however, in other experimental systems to demonstrate the
antigen specificity of Foxp3+ T cells ex vivo (Hsieh et al., 2006;
Pacholczyk et al., 2007). It is most likely that among the large
numbers of activated Foxp3+ T cells, many of which are actively
dividing (30%, compared to 15% in tumor-free mice, as evi-
denced by their staining with KI67, data not shown), some are
specific for tumor antigens, including OVA. Given that OVA is
a non-self-antigen, it is also most likely that the polyclonal reper-
toire of Foxp3+ T cells also includes this specificity.
Unfortunately, we failed to detect efficient cytotoxicity in vitro
using the endogenous Foxp3+ T cells. Indeed, significant cyto-
toxic activity is seen for a ratio of at least five OVA-specific
Foxp3+ T cell per DC. Reaching such ratios in vitro with endog-enous Foxp3+ T cells is probably not easy because of the likely
low frequency of antigen-specific Foxp3+ T cells.
Our findings identify a possible mode of regulation of CD8+
T cell priming by Foxp3+ T cells: by killing tumor antigen-present-
ing DCs in tdLNs, Foxp3+ T cells limit the efficiency of T cell
priming against tumor antigens. Whether this mode of regulation
is specific for tumors or may represent a more general mecha-
nism of Treg cell-mediated inhibition of immune responses will
be addressed in future studies. Nevertheless, if Foxp3+ T cells
are also cytotoxic to tumor-antigen bearing DCs in humans,
DC killing may contribute to limit the efficiency of DC-mediated
vaccination in cancer patients.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 female mice were obtained from Charles River, (Les Oncins, France)
and used between 6–10 weeks old. We crossed C57BL/6 Rag2–/– TCR
(Va2, Vb5) transgenic mice (OTI) with UBI-GFP/BL6 or with the Actb-ECFP/
BL6 to obtain the OTI-GFP and OTI-CFP mice, respectively (Boissonnas
et al., 2007). B6-Foxp3tm1Mal mice (called Foxp3-EGFP mice here) (Wang
et al., 2008), DEREG mice (Lahl et al., 2007), perforin-deficient mice
(Ka¨gi et al., 1994), and Marilyn mice (Lantz et al., 2000) were described previ-
ously. We crossed Foxp3-EGFP mice with transgenic OTII mice to obtain OTII-
Foxp3-EGFP mice. Live-animal experiments were done in accordance with
the guidelines of the French Veterinary Department.
Cells
CD8+ OTI T cells (specific for OVA257-264 peptide in a H2-K
b context) were
obtained from lymph nodes of OTI Rag2/ (called OTI T cells here) mice
(purity 96%). Marilyn CD4+ T cells were obtained from lymph nodes of Mari-
lyn Rag2/ mice and stained with 5 mM 5-(and-6)-(((4-chloromethyl)benzoy-
l)amino)tetramethylrhodamine (CMTMR, Invitrogen, Cergy Pontoise, France)
in PBS during 10 min at 37C. CD4+ GFP+ and CD4+GFP T cells were purified
by flow cytometry and stimulated in vitro (in medium containing 2000 IU/Ml
rhIL-2 (Chiron Corp), with LPS (1 mg/ml)-treated, OVA323-339 peptide (1 mM)-
pulsed, bone marrow-derived DCs. After 5 days, IL-2 supplemented medium
was added to the culture. Cells were collected after 8–9 days. For the two-
photon imaging experiments, bone marrow-derived DCs, differentiated as
previously described (Naik et al., 2005), were loaded with 1 mM OVA323-339
for 1 hr, washed, and labeled with 1 mM Hoechst in PBS during 10 min at
37C before staining with 5 mM CMTMR in PBS during 10 min at 37C. The cells
were injected s.c. in the flank of tumor-bearing or tumor-free mice. The
MCA101 (MCA) cell line was stably transfected with an control plasmid or
a plasmid encoding for soluble Ovalbumin (OVA) for generation of the control
MCA-Mock and MCA-OVA, respectively (Zeelenberg et al., 2008). All cell lines
were cultured in DMEM (Gibco, Invitrogen, Cergy Pontoise, France) supple-
mented with antibiotics and 10% FCS.
In Vivo Tumor Growth and Cell Depletions
MCA-OVA cells were injected subcutaneously in the flank of mice and the
tumor size was measured twice a week with a caliper, V = L 3 l 3 (L + l)/2.
The same day, the mice were injected with 400 mg of anti-CD25 (PC61) or rat
IgG1 isotype control (HRPN) (BioXcell, West Lebanon NH, USA). For imaging
of DC death, PC61 was injected at day 2 after tumor inoculation. Serum quan-
tification of Rat IgG was performed by ELISA (Bethyl, Montgomery, TX, USA).
For DEREG mice and littermates, 1mg of DTx (Merck, Nottingham, UK) was
injected intraperitoneally (i.p.) in PBS at days 3 and 4, at days 8–9, and at
days 13–14 after tumor inoculation to induce and maintain Foxp3+ T cell deple-
tion. Ten days after tumor inoculation 5 3 106 naive OTI T cells were injected
intravenously (i.v.) CD8+ T cells and NK cells were depleted 24 hours before
imaging; injecting i.p. 200 mg of both H35 and PK136 clones respectively.
Flow Cytometry
Phenotypic characterization of T cells was performed using a FACSCalibur
(Becton Dickinson Franklin Lakes, NJ, USA). MCA-tumor, draining (axillary),Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc. 275
Immunity
Dendritic Cell Killing by Foxp3+ T Cellsand nondraining (the 2 popliteal) lymph nodes were harvested at different days
after tumor inoculation or adoptive transfer of naive OTI T cells. Cell suspen-
sions were prepared in PBS 0.5% BSA, and cells were labeled regarding the
experiment with anti-CD69-PerCPCy5.5 (clone H1.2F3), anti-CD62L-APC
(clone MEL-14), anti-CD44-PE (clone IM-7), anti-CD8-APC (clone 53-6.7),
anti-CD11b-PercP-Cy5.5 (clone M1/70), anti-CD11c-PE or -APC (clone
HL3), anti-CD80-FITC (clone 16-10A1), anti-ICAM-1-FITC (clone 3E2), anti-
CD40-PE (clone 3/23), and anti-I-Ab-PE (clone AF6-120.1) (BD Biosciences,
San Jose, USA). Regulatory T cells were discriminated by labeling with
anti-CD25-PercPCy5.5 (clone PC61), anti-CD4-APC (clone RM4-5, BD
Biosciences, San Jose, USA) and for Foxp3 through GFP expression from
Foxp3-EGFP mice. For intracellular cytokine staining, cell suspensions were
incubated for 3 hr at 37C in the presence of 5 mg/ml Brefeldin A, fixed in
2% PFA, and incubated in PBS 0.5% BSA with saponin at 0.1% in the pres-
ence of anti-IFN-g-APC (clone XMG1.2). For anti-perforin-PE (Clinisciences,
Montrouge, France), anti-Granzyme B-PE (clone GB12, Caltag, Invitrogen)
and anti-Foxp3-APC (clone FJK-16s, Clinisciences, Montrouge, France) stain-
ing, fixation and permeabilization were performed with Foxp3 staining kit
(Clinisciences) in accordance with the manufacturer’s instructions. For CFSE
experiments, CD45.1 OTI T cells were incubated for 10 min at 37C in PBS
with 5 mM CFSE (Molecular Probes, Invitrogen). A total of 5 3 106 cells were
injected in PBS into CD45.2 tumor-bearing or tumor-free mice. After 4 or
6 days, CFSE dilution in axillary LNs was measured, while gating on CD45.1
(A20) CD8+ T cells.
Two-Photon Laser-Scanning Microscopy
A total of 53106 naive CFP-expressing OTI T cells were injected i.v. to Foxp3-
EGFP tumor-bearing recipients. All imaging experiments were performed on
explanted tissue. LNs were carefully collected and were immobilized in an
imaging chamber perfused with oxygenated (95% O2 plus 5% CO2) RPMI
medium containing 10% FCS. Local temperature was monitored and main-
tained at 37C. Lymph node imaging was performed 24 hr after adoptive trans-
fer. T cells could be detected up to 200 mm from the surface of LNs.
Measurements were performed in at least three independent experiments.
The two-photon laser-scanning microscopy (TPLSM) setup used was an
LSM510 Meta (Zeiss, Jena, Germany) coupled to a Maitai DeepSee femto-
second laser (690–1020 nm) (Spectra-Physics, Mountain View, CA, USA).
Three fluorescence channels were recorded simultaneously with two dichroic
mirrors (495 nm and 555 nm) in combination with 472/30 (CFP/Hoechst), 520/
35 (GFP), and 585/40 (CMTMR) bandpass filters. The excitation wavelength
was 850 nm. For analysis of cell migration, every 30s during 30–60 min, six
consecutive 230 3 230 mm2 images, with 6 mm z spacing with an 40 3 0.8w
objective were taken. Images were average-projected with Image J software
(NIH), and manual tracking of individual cells was performed with Metamorph
software. The acquisition and analysis protocols for all experimental condi-
tions to be compared were identical. The arrest coefficient is defined as the
proportion of time each cell’s instantaneous velocity (calculated for every
30 s interval) is lower than 2 mm/min. The confinement ratio corresponds to
the ratio of the distance between the initial and the final positions of each
cell to the total distance covered by the same cell. In all our quantifications,
only direct contacts between corpses of Foxp3+ T cells and DCs were taken
into account. Putative distant contacts through dendrites were not considered.
The overestimation of cell-to-cell contacts due to the z projections performed
for the quantifications is most likely small (especially for long-lasting contacts)
and is similar for all conditions. The interaction number/hour represent the
number of new contact made by each DC with a Foxp3+ T cell reported during
1 hr and normalized to the density of Foxp3+ T cells in the field. Cumulated
contact duration represents the cumulated duration of total contact made by
each DC with Foxp3+ T cells during 1 hr and normalized to the density of
Foxp3+ T cells in the field. The density of Foxp3+ T cells was given by the
mean of the number of Foxp3+ T cells measured at different time points in
the field reported to the volume of the field analyzed.
In Vitro Cytotoxic Assay
OTII T cells were cocultured for 20 hr with DCs isolated from tdLNs or LNs from
tumor-free mice with anti-CD11c-magnetic beads (Miltenyi, Paris, France). For
each condition, purified DCs were either loaded with 1 mM OVA323-339 and
labeled with 2 mM CFSE (CFSEhi) or directly labeled with 0.2 mM CFSE (CFSElo).276 Immunity 32, 266–278, February 26, 2010 ª2010 Elsevier Inc.Percentages of antigen-specific lysis were calculated with the following
formula:
% of antigen-specific lysis=

1 

% CFSEhi=% CFSElo
.

% CFSEhi ctrl=% CFSElo ctrl

3 100
Control corresponds to DCs cultured in absence of T cells.
Statistical Analysis and Normalization
Two-way ANOVA, student t tests, and Spearman correlation tests were
performed for statistic experiments. For p values, *p < 0.05; **p < 0.01,
***p < 0.001, and ‘‘ns’’ is defined as not significant.
For each experiment, the mean percent or number of CD11c+ cells in mice
(three to five mice) from the control groups was calculated. The percent or
number of CD11c+ cells from each individual control and treated mouse was
normalized to the mean of the control of the corresponding experiment (by
dividing the value for each mouse—control and treated—by the mean of the
control group and expressed as a percentage). The graphs presented in
Figures 3B and 5C represent the mean of all the normalized values from all
experiments obtained according to this procedure.
The statistical analysis of the nonnormalized results shown in Figures 3B,
3C, 5C, and 5D was performed with the two-way ANOVA test, as detailed
in Figure S9.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and seven movies and can be
found with this article online at doi:10.1016/j.immuni.2009.11.015.
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